Dedicated to transforming the care of people living with Rare Genetic Disorders of Obesity

"When Tysen was three he was fifty pounds, when Mike was three he was eighty pounds."

Mike and Tysen, father and son living with MC4R Pathway Heterozygous Obesity

Joan, wife to Mike and mother to Tysen, both diagnosed with MC4R Pathway Heterozygous Obesity

"Alström syndrome has a high impact on her weight...she constantly wants to eat and can't get enough."

Leigha, living with Alström syndrome

Breezy, mother of Leigha, diagnosed with Alström syndrome

"I think the biggest thing to try to get people to understand is the constant hunger issue."

Solomon and Adalissa, siblings living with Bardet-Biedl syndrome

Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome

"When Tysen was three he was fifty pounds, when Mike was three he was eighty pounds."

Joan, wife to Mike and mother to Tysen, both diagnosed with MC4R Pathway Heterozygous Obesity

Mike and Tysen, father and son living with MC4R Pathway Heterozygous Obesity
"Alström syndrome has a high impact on her weight...she constantly wants to eat and can't get enough."

Breezy, mother of Leigha, diagnosed with Alström syndrome

Leigha, living with Alström syndrome
"I think the biggest thing to try to get people to understand is the constant hunger issue."

Olivia, Mother of Adalissa and Solomon, both diagnosed with Bardet Biedl syndrome

Solomon and Adalissa, siblings living with Bardet-Biedl syndrome

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.


By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic disorders of obesity, including:

Proopiomelanocortin
(POMC) Deficiency Obesity
Leptin Receptor (LEPR)
Deficiency Obesity
Bardet-Biedl
Syndrome (BBS)
Alström
Syndrome
POMC or LEPR
Heterozygous Deficiency Obesity
Smith-Magenis
Syndrome
SRC1 Deficiency
Obesity
MC4R Deficiency
Obesity
SH2B1 Deficiency
Obesity

Our news

2020-11-27T07:30:00

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

2020-11-04T16:30:00

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

2020-11-02T08:00:00

Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results